India’s vaccine nationalism is a global risk | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
May 29, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, MAY 29, 2025
India’s vaccine nationalism is a global risk

Analysis

Andy Mukherjee, Bloomberg
04 January, 2021, 04:25 pm
Last modified: 04 January, 2021, 04:55 pm

Related News

  • Shrimp fry worth Tk1cr seized in Cumilla while being smuggled to India
  • India's alarm over Chinese spying rocks the surveillance industry
  • 31 more people pushed into Bangladesh through Kurigram, C’Nawabganj borders
  • 36 trafficked Bangladeshis return after serving jail terms in India
  • BSF pushes in 23 more people through Satkhira border, says BGB

India’s vaccine nationalism is a global risk

The country has approved a domestically developed jab that does not yet have critical phase three data

Andy Mukherjee, Bloomberg
04 January, 2021, 04:25 pm
Last modified: 04 January, 2021, 04:55 pm
The indigenous vaccine. Photographer: NurPhoto/NurPhoto
The indigenous vaccine. Photographer: NurPhoto/NurPhoto

Like many things in India nowadays, the science of vaccine approval has also run into the politics of chest-thumping nationalism.

Alongside authorizing Covishield, the Covid-19 protection developed by Oxford University and AstraZeneca Plc and manufactured by the Serum Institute of India Ltd., the country's drugs regulator on Sunday gave a go-ahead to an indigenous vaccine for which critical phase three trial data isn't yet available.

The hasty nod for Bharat Biotech International Ltd.'s Covaxin, developed in collaboration with the Indian Council of Medical Research and National Institute of Virology, has raised eyebrows in the scientific and healthcare communities about a "public rollout of an untested product," according to a national network of nongovernment organizations.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

This is unfortunate. With more than 10 million coronavirus infections, India is the world's second-worst-affected nation after the U.S. New Delhi's strategy for vaccinating 1.3 billion people will matter greatly for bringing the global pandemic to a decisive end. The country's virus-battered economy and its overstretched health systems are also yearning for a reprieve. It will be dangerous to allow political calculations to enter the equation and shake people's confidence in what's being offered to them — and on what basis.

That's just what seems to be happening with the unusual approval for Covaxin, which comes with the odd caveat that its use will be restricted to "public interest as an abundant precaution, in clinical trial mode, especially in the context of mutant strains." Nobody seems to know what this will mean on the ground. Who'll get Covishield, and who'll be given Covaxin? More importantly, who'll decide? In a country beset by massive inequalities in income, wealth and social status, these aren't trivial questions. 

When opposition leaders raised doubts about the vaccine selection process, a minister in Prime Minister Narendra Modi's cabinet likened their objections to questioning "the valor of our soldiers."

To be sure, India is not even in the front row of vaccine nationalism. China and Russia are more desperate to beat the West in saving the world. But as my colleague Clara Ferreira Marques has noted, both countries' vaccine candidates face a transparency deficit, which could limit their global acceptance. 

That's a risk that India, which manufactures more than 60% of the world's vaccines, should avoid at all cost. According to media reports, Hyderabad, India-based Bharat Biotech has enlisted 23,000 volunteers for phase three clinical trials. That's encouraging because another report, published last month, had cited a major New Delhi-based research hospital as saying that it couldn't find enough subjects for the study. If the drug proves to be effective, introducing it even at a later date should pose no problems. Naming Covaxin as an alternative even in the absence of phase three data could be a commercial tactic to squeeze "better discounts" on bulky Covishield purchase contracts, brokerage Jefferies says. Still, cutting corners with science isn't exactly the best strategy to negotiate drug prices. 

The Kremlin-backed Sputnik V is also undergoing trials in India, in partnership with local manufacturer Dr. Reddy's Laboratories Ltd. The Ahmedabad-based Cadila Healthcare Ltd. is also in the race to develop an indigenous Covid-19 vaccine. Ultimately, it doesn't matter whether India's homegrown shots make the final cut. Serum Institute, the world's largest producer, has already stockpiled 70 million doses of Covishield. Big parts of the developing world will rely on Indian manufacturers to supply easy-to-administer, affordably priced vaccines in large quantities.

Nationalism can only muddy the waters with vacuous slogans and irrational goals. The Indian Council of Medical Research was pushing Bharat Biotech to launch Covaxin by Aug. 15, India's independence day. Thankfully, that deadline came and went. But the impatience we saw back then is once again rearing its head when the message for India should be the exact opposite. Properly designed and implemented studies, honestly reported side effects, and transparently shared efficacy data will boost the world's confidence in Made in India jabs. Cutting corners will damage trust. It'll be helpful to leave soldiers alone, and stick to science — and established scientific protocols. 


Andy Mukherjee is a Bloomberg Opinion columnist covering industrial companies and financial services. He previously was a columnist for Reuters Breakingviews. He has also worked for the Straits Times, ET NOW and Bloomberg News.

Disclaimer: This article first appeared on bloomberg.com, and is published by special syndication arrangement.

Top News

India / vaccines / nationalism

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational Photo: Collected
    Tax gap between listed and non-listed firms may widen to 7.5% 
  • Officials protest inside the Secretariat on Tuesday, 27 May 2025, over a government ordinance amending the Public Service Act, 2018. Photo: Rajib Dhar
    Secretariat staff observe 1-hr work abstention
  • Representational image. Freepik
    Govt likely to trim subsidies in new budget

MOST VIEWED

  • Google Pay. Photo: Collected
    Google Pay likely coming to Bangladesh soon
  • IFIC Bank receives Tk6,000 cr in new deposits in six months
    IFIC Bank receives Tk6,000 cr in new deposits in six months
  • Dhaka areas at a gridlock on Wednesday, 28 May 2025. Photo: Syed Zakir Hossain/TBS
    BNP, Jamaat rallies: Traffic clogs Dhaka roads, including Motijheel, Paltan, Dainik Bangla intersection
  • Abdul Awal Mintoo, chairman of National Bank Limited. Sketch: TBS
    'Regulatory support must for National Bank to restore depositors' confidence'
  • Mohammad Abdul Mannan, chairman FSIB Ltd. Sketch: TBS
    FSIB to bounce back soon
  • Mohammad Mamdudur Rashid, managing director and CEO, UCB. Sketch: TBS
    Customers’ trust and confidence fueling deposit growth at UCB

Related News

  • Shrimp fry worth Tk1cr seized in Cumilla while being smuggled to India
  • India's alarm over Chinese spying rocks the surveillance industry
  • 31 more people pushed into Bangladesh through Kurigram, C’Nawabganj borders
  • 36 trafficked Bangladeshis return after serving jail terms in India
  • BSF pushes in 23 more people through Satkhira border, says BGB

Features

In recent years, the Gor-e-Shaheed Eidgah has emerged as a strong contender for the crown of the biggest Eid congregation in the country, having hosted 600,000 worshippers in 2017. Photo: TBS

Gor-e-Shaheed Boro Maath: The heart of Dinajpur

2d | Panorama
The Hili Land Port, officially opened in 1997 but with trade roots stretching back to before Partition, has grown into a cornerstone of bilateral commerce.

Dhaka-Delhi tensions ripple across Hili’s markets and livelihoods

3d | Panorama
Photo: Collected

Desk goals: Affordable ways to elevate your study setup

3d | Brands
Built on a diamond-type frame, the Hornet 2.0 is agile but grounded. PHOTO: Asif Chowdhury

Honda Hornet 2.0: Same spirit, upgraded sting

3d | Wheels

More Videos from TBS

Low Pressure over the Bay of Bengal, Signal No. 3 Issued for Sea Ports

Low Pressure over the Bay of Bengal, Signal No. 3 Issued for Sea Ports

44m | TBS Today
The fight between two brothers; Adidas vs Puma

The fight between two brothers; Adidas vs Puma

11h | Others
Trump is again keen to make Canada the 51st state

Trump is again keen to make Canada the 51st state

12h | Others
Trump's tariff strategy and Europe's investment politics, violence or negotiation?

Trump's tariff strategy and Europe's investment politics, violence or negotiation?

13h | Others
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net